Search

Your search keyword '"Van Damme, Pierre"' showing total 1,963 results
Start Over Author "Van Damme, Pierre"
1,963 results on '"Van Damme, Pierre"'

4. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

Author

Larivière, Ynke, Matuvanga, Trésor Zola, Osang'ir, Bernard Isekah, Milolo, Solange, Meta, Rachel, Kimbulu, Primo, Robinson, Cynthia, Katwere, Michael, McLean, Chelsea, Lemey, Gwen, Matangila, Junior, Maketa, Vivi, Mitashi, Patrick, Van geertruyden, Jean-Pierre, Van Damme, Pierre, and Muhindo-Mavoko, Hypolite

Published
2024
Full Text
View/download PDF

5. Lessons from COVID-19 for behavioural and communication interventions to enhance vaccine uptake

Author

Lewandowsky, Stephan, Schmid, Philipp, Habersaat, Katrine Bach, Nielsen, Siff Malue, Seale, Holly, Betsch, Cornelia, Böhm, Robert, Geiger, Mattis, Craig, Brett, Sunstein, Cass, Sah, Sunita, MacDonald, Noni E., Dubé, Eve, Fancourt, Daisy, Larson, Heidi J., Jackson, Cath, Mazhnaya, Alyona, Dutta, Mohan, Fountoulakis, Konstantinos N., Kachkachishvili, Iago, Soveri, Anna, Caserotti, Marta, Őri, Dorottya, de Girolamo, Giovanni, Rodriguez-Blazquez, Carmen, Falcón, Maria, Romay-Barja, Maria, Forjaz, Maria João, Blomquist, Sarah Earnshaw, Appelqvist, Emma, Temkina, Anna, Lieberoth, Andreas, Harvey, T. S., Holford, Dawn, Fasce, Angelo, Van Damme, Pierre, and Danchin, Margie

Published
2023
Full Text
View/download PDF

7. Lack of functional TCR-epitope interaction is associated with herpes zoster through reduced downstream T cell activation

Author

Boeren, Marlies, de Vrij, Nicky, Ha, My K., Valkiers, Sebastiaan, Souquette, Aisha, Gielis, Sofie, Kuznetsova, Maria, Schippers, Jolien, Bartholomeus, Esther, Van den Bergh, Johan, Michels, Nele, Aerts, Olivier, Leysen, Julie, Bervoets, An, Lambert, Julien, Leuridan, Elke, Wens, Johan, Peeters, Karin, Emonds, Marie-Paule, Elias, George, Vandamme, Niels, Jansens, Hilde, Adriaensen, Wim, Suls, Arvid, Vanhee, Stijn, Hens, Niel, Smits, Evelien, Van Damme, Pierre, Thomas, Paul G., Beutels, Philippe, Ponsaerts, Peter, Van Tendeloo, Viggo, Delputte, Peter, Laukens, Kris, Meysman, Pieter, and Ogunjimi, Benson

Published
2024
Full Text
View/download PDF

12. Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics

Author

Busch, Martin, Seifert, Ulrike, Widmer, Andreas, Nagao, Miki, Rello, Jordi, Todorova, Tatina, Cviljević, Sabina, Heath, Christopher H., Jančorienė, Ligita, Fischer, Thea Koelsen, Orth, Hans Martin, Johansen, Isik Somuncu, Doymaz, Mehmet, Tragiannidis, Athanasios, Löscher, Thomas, Xu, Jin-Fu, Husa, Petr, Oteo, José Antonio, Issack, Mohammad I., Zeitlinger, Markus, Le Grand, Roger, Zdziarski, Przemysław, Demirkan, Fatih, Amador, Paloma Merino, García-Lozano, Tomás, Cao, Qing, Vázquez, Lourdes, Caeiro, Juan Pablo, Hermans, Peter, Nahrwar, Shahroch, Avsar, Korkut, Kumar, Deepak, Fernández, Norma, Mardani, Masoud, Segal, Esther, Pan, Angelo, Gkentzi, Despoina, Gioula, Georgia, Cortés, Jorge Alberto, Oliveira, Joaquim, van Damme, Pierre, Bin Mohd Zaili, Mohd Zaki, Antinori, Spinello, Zablockienė, Birutė, Papazisis, Georgios, Aneke, Chioma Inyang, Valerio, Maricela, McConkey, Samuel, Aujayeb, Avinash, Azzini, Anna Maria, Roganović, Jelena, Greve-Isdahl Mohn, Kristin, Kremsner, Peter, Gkrania-Klotsas, Effrossyni, Corzo, Dora, Khanna, Nina, Smiatacz, Tomasz, Scheithauer, Simone, Merelli, Maria, Klempa, Boris, Vrḫovac, Radovan, Ruggiero, Antonio, Chaudhary, Pankaj, Maquera-Afaray, Julio, Ekkelenkamp, Miquel, Jindra, Pavel, Pantić, Nikola, Guerra, Gemma Jiménez, Weiss, Guenter, Roohi, Behrad, Argyropoulos, Christos D., Silfverdal, Sven Aprne, van Praet, Jens, Bal, Zumrut Sahbudak, Kanj, Souha, Young, Barnaby, Pana, Zoi Dorothea, Roilides, Emmanuel, Stearns, Stephen C., Wauters, Joost, Baño, Jesús Rodríguez, Pletz, Mathias W., Travar, Maja, Kühn, Steven, Riera, Fernando, Cornely, Daniel, Laura, Vlad Jeni, Koehler, Philipp, Eley, Brian, Nair, Pravin K., Ciesek, Sandra, Olaru, Ioana Diana, Marques, Laura, Pontali, Emanuele, Naunheim, Alexandra, Lieb, Adrian, Gerhard, Markus, Farooqi, Joveria Qais, Turtle, Lance, Méndez, Gustavo Adolfo, Cox, Rebecca Jane, Goodman, Nigel, Caceca, Billie, Pemán, Javier, Dawood, Halima, Askling, Helena Hervius, Fomsgaard, Anders, Hernández, Alejandra Calderón, Staehelin, Cornelia, Liu, Chia-Ying, Icardi, Giancarlo, Castagnola, Elio, Salzer, Helmut J.F., Lundgren, Jens, Javadli, Samir, Forghieri, Fabio, Salmanton-García, Jon, Wipfler, Pauline, Leckler, Janina, Nauclér, Pontus, Mallon, Patrick W., Bruijning-Verhagen, Patricia C.J.L., Schmitt, Heinz-Joseph, Bethe, Ullrich, Olesen, Ole F., Stewart, Fiona A., Albus, Kerstin, and Cornely, Oliver A.

Published
2024
Full Text
View/download PDF

14. VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe

Author

Salmanton-García, Jon, Wipfler, Pauline, Valle-Simón, Paula, Merakou, Christina, Kopsidas, Ioannis, Bethe, Ullrich, Steinbach, Angela, Spivak, Orly, Součková, Lenka, Mendonça, Maria Amélia, Koniordou, Markela, Hellemans, Margot, Frías-Iniesta, Jesus, Davis, Ruth Joanna, Barta, Imre, Azzini, Anna Maria, Askling, Helena H., Argyropoulos, Christos D., Álvarez-Barco, Elena, Akova, Murat, Bonten, Marc M.J., Cohen-Kandli, Miriam, Cox, Rebecca Jane, Flisiak, Robert, Husa, Petr, Jancoriene, Ligita, Koscalova, Alena, Launay, Odile, Lundgren, Jens, Mallon, Patrick, Marques, Laura, Nauclér, Pontus, Ochando, Jordi, Pana, Zoi-Dorothea, Tacconelli, Evelina, Tóth, Krisztina, Trelle, Sven, van Damme, Pierre, Zaoutis, Theoklis E., Zeitlinger, Markus, Albus, Kerstin, Stewart, Fiona A., Hofstraat, Sanne H.I., Bruijning-Verhagen, Patricia, and Cornely, Oliver A.

Published
2023
Full Text
View/download PDF

15. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial

Author

Tschismarov, Roland, Van Damme, Pierre, Germain, Clara, De Coster, Ilse, Mateo, Mathieu, Reynard, Stephanie, Journeaux, Alexandra, Tomberger, Yvonne, Withanage, Kanchanamala, Haslwanter, Denise, Terler, Katherine, Schrauf, Sabrina, Müllner, Matthias, Tauber, Erich, Ramsauer, Katrin, and Baize, Sylvain

Published
2023
Full Text
View/download PDF

16. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

Author

Vesikari, Timo, Langley, Joanne M, Gantt, Soren, Dionne, Marc, McElhaney, Janet, Rankin, Bruce, Griffin, Carl, Turner, Mark, Kirstein, Judith, Rizzardi, Barbara E, Williams, Hayes, Ahonen, Anitta, Henriksson, Olli, Ukkonen, Benita, Paassilta, Marita, Segall, Nathan, Ward, Brian J, Cooper, Curtis, Poliquin, Guillaume, Smith, Bruce, Van Damme, Pierre, Leroux-Roels, Isabel, Leroux-Roels, Geert, Machluf, Nathalie, Spaans, Johanna N, Yassin-Rajkumar, Bebi, Anderson, David E, Popovic, Vlad, Diaz-Mitoma, Francisco, McElhaney, Janet E, and van Damme, Pierre

Published
2021
Full Text
View/download PDF

20. An ancillary care policy in a vaccine trial conducted in a resource-constrained setting: evaluation and policy recommendations

Author

Lemey, Gwen, primary, Larivière, Ynke, additional, Osang'ir, Bernard Isekah, additional, Zola, Trésor, additional, Kimbulu, Primo, additional, Milolo, Solange, additional, Danoff, Engbu, additional, Tchuma, Yves, additional, Maketa, Vivi, additional, Mitashi, Patrick, additional, Ravinetto, Raffaella, additional, Van Damme, Pierre, additional, Van geertruyden, Jean-Pierre, additional, and Muhindo-Mavoko, Hypolite, additional

Published
2024
Full Text
View/download PDF

22. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study

Author

Van Damme, Pierre, De Coster, Ilse, Bandyopadhyay, Ananda S, Revets, Hilde, Withanage, Kanchanamala, De Smedt, Philippe, Suykens, Leen, Oberste, M Steven, Weldon, William C, Costa-Clemens, Sue Ann, Clemens, Ralf, Modlin, John, Weiner, Amy J, Macadam, Andrew J, Andino, Raul, Kew, Olen M, Konopka-Anstadt, Jennifer L, Burns, Cara C, Konz, John, Wahid, Rahnuma, and Gast, Christopher

Subjects
Clinical Research, Biotechnology, Infectious Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Prevention, Immunization, Vaccine Related, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Infection, Good Health and Well Being, Adult, Antibodies, Viral, Double-Blind Method, Feces, Female, Humans, Immunogenicity, Vaccine, Male, Middle Aged, Poliomyelitis, Poliovirus, Poliovirus Vaccine, Oral, RNA, Viral, Single-Blind Method, Vaccines, Attenuated, Virulence, Virus Shedding, Young Adult, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundUse of oral live-attenuated polio vaccines (OPV), and injected inactivated polio vaccines (IPV) has almost achieved global eradication of wild polio viruses. To address the goals of achieving and maintaining global eradication and minimising the risk of outbreaks of vaccine-derived polioviruses, we tested novel monovalent oral type-2 poliovirus (OPV2) vaccine candidates that are genetically more stable than existing OPVs, with a lower risk of reversion to neurovirulence. Our study represents the first in-human testing of these two novel OPV2 candidates. We aimed to evaluate the safety and immunogenicity of these vaccines, the presence and extent of faecal shedding, and the neurovirulence of shed virus.MethodsIn this double-blind, single-centre phase 1 trial, we isolated participants in a purpose-built containment facility at the University of Antwerp Hospital (Antwerp, Belgium), to minimise the risk of environmental release of the novel OPV2 candidates. Participants, who were recruited by local advertising, were adults (aged 18-50 years) in good health who had previously been vaccinated with IPV, and who would not have any contact with immunosuppressed or unvaccinated people for the duration of faecal shedding at the end of the study. The first participant randomly chose an envelope containing the name of a vaccine candidate, and this determined their allocation; the next 14 participants to be enrolled in the study were sequentially allocated to this group and received the same vaccine. The subsequent 15 participants enrolled after this group were allocated to receive the other vaccine. Participants and the study staff were masked to vaccine groups until the end of the study period. Participants each received a single dose of one vaccine candidate (candidate 1, S2/cre5/S15domV/rec1/hifi3; or candidate 2, S2/S15domV/CpG40), and they were monitored for adverse events, immune responses, and faecal shedding of the vaccine virus for 28 days. Shed virus isolates were tested for the genetic stability of attenuation. The primary outcomes were the incidence and type of serious and severe adverse events, the proportion of participants showing viral shedding in their stools, the time to cessation of viral shedding, the cell culture infective dose of shed virus in virus-positive stools, and a combined index of the prevalence, duration, and quantity of viral shedding in all participants. This study is registered with EudraCT, number 2017-000908-21 and ClinicalTrials.gov, number NCT03430349.FindingsBetween May 22 and Aug 22, 2017, 48 volunteers were screened, of whom 15 (31%) volunteers were excluded for reasons relating to the inclusion or exclusion criteria, three (6%) volunteers were not treated because of restrictions to the number of participants in each group, and 30 (63%) volunteers were sequentially allocated to groups (15 participants per group). Both novel OPV2 candidates were immunogenic and increased the median blood titre of serum neutralising antibodies; all participants were seroprotected after vaccination. Both candidates had acceptable tolerability, and no serious adverse events occurred during the study. However, severe events were reported in six (40%) participants receiving candidate 1 (eight events) and nine (60%) participants receiving candidate 2 (12 events); most of these events were increased blood creatinine phosphokinase but were not accompanied by clinical signs or symptoms. Vaccine virus was detected in the stools of 15 (100%) participants receiving vaccine candidate 1 and 13 (87%) participants receiving vaccine candidate 2. Vaccine poliovirus shedding stopped at a median of 23 days (IQR 15-36) after candidate 1 administration and 12 days (1-23) after candidate 2 administration. Total shedding, described by the estimated median shedding index (50% cell culture infective dose/g), was observed to be greater with candidate 1 than candidate 2 across all participants (2·8 [95% CI 1·8-3·5] vs 1·0 [0·7-1·6]). Reversion to neurovirulence, assessed as paralysis of transgenic mice, was low in isolates from those vaccinated with both candidates, and sequencing of shed virus indicated that there was no loss of attenuation in domain V of the 5'-untranslated region, the primary site of reversion in Sabin OPV.InterpretationWe found that the novel OPV2 candidates were safe and immunogenic in IPV-immunised adults, and our data support the further development of these vaccines to potentially be used for maintaining global eradication of neurovirulent type-2 polioviruses.FundingBill & Melinda Gates Foundation.

Published
2019

23. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial

Author

Folschweiller, Nicolas, Vanden Abeele, Carline, Chu, Laurence, Van Damme, Pierre, García-Sastre, Adolfo, Krammer, Florian, Nachbagauer, Raffael, Palese, Peter, Solórzano, Alicia, Bi, Dan, David, Marie-Pierre, Friel, Damien, Innis, Bruce L, Koch, Juliane, Mallett, Corey P, Rouxel, Ronan Nicolas, Salaun, Bruno, Vantomme, Valerie, Verheust, Céline, and Struyf, Frank

Published
2022
Full Text
View/download PDF

24. Blood transcriptomics to facilitate diagnosis and stratification in pediatric rheumatic diseases – a proof of concept study

Author

Ha, My Kieu, Bartholomeus, Esther, Van Os, Luc, Dandelooy, Julie, Leysen, Julie, Aerts, Olivier, Siozopoulou, Vasiliki, De Smet, Eline, Gielen, Jan, Guerti, Khadija, De Maeseneer, Michel, Herregods, Nele, Lechkar, Bouchra, Wittoek, Ruth, Geens, Elke, Claes, Laura, Zaqout, Mahmoud, Dewals, Wendy, Lemay, Annelies, Tuerlinckx, David, Weynants, David, Vanlede, Koen, van Berlaer, Gerlant, Raes, Marc, Verhelst, Helene, Boiy, Tine, Van Damme, Pierre, Jansen, Anna C., Meuwissen, Marije, Sabato, Vito, Van Camp, Guy, Suls, Arvid, Werff ten Bosch, Jutte Van der, Dehoorne, Joke, Joos, Rik, Laukens, Kris, Meysman, Pieter, and Ogunjimi, Benson

Published
2022
Full Text
View/download PDF

26. Healthcare Providers' and Frontline Workers' Experiences of an Ebola Vaccine Trial in the Boende Health District of the Democratic Republic of the Congo.

Author

Zola Matuvanga, Trésor, Bikioli Bolombo, Freddy, Paviotti, Antea, Larivière, Ynke, Lemey, Gwen, Salloum, Maha, Isekah Osang'ir, Bernard, Matangila, Junior, Maketa, Vivi, Esanga, Emmanuel, Milolo, Solange, Mitashi, Patrick, Van Damme, Pierre, Muhindo-Mavoko, Hypolite, and Van Geertruyden, Jean-Pierre

Published
2024
Full Text
View/download PDF

28. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials

Author

De Coster, Ilse, Leroux-Roels, Isabel, Bandyopadhyay, Ananda S, Gast, Christopher, Withanage, Kanchanamala, Steenackers, Katie, De Smedt, Philippe, Aerssens, Annelies, Leroux-Roels, Geert, Oberste, M Steven, Konopka-Anstadt, Jennifer L, Weldon, William C, Fix, Alan, Konz, John, Wahid, Rahnuma, Modlin, John, Clemens, Ralf, Costa Clemens, Sue Ann, Bachtiar, Novilia S, and Van Damme, Pierre

Published
2021
Full Text
View/download PDF

30. Primary Healthcare Providers' Views on Periodic COVID-19 Booster Vaccination for Themselves and Their Patients: A 2023 Nationwide Survey in Belgium.

Author

Digregorio, Marina, Van Ngoc, Pauline, Domen, Julie, Bognar, Zsofia, Duysburgh, Els, Hendrickx, Greet, Van Damme, Pierre, Coenen, Samuel, and Scholtes, Beatrice

Subjects
BOOSTER vaccines, MEDICAL personnel, MEDICAL care, VACCINE effectiveness, VACCINE hesitancy
Abstract

New COVID-19 strains and waning vaccine effectiveness prompted initiatives for booster vaccination. In Belgium, healthcare providers (HCPs) received a second booster in July 2022, with eligible individuals receiving a third in autumn. Primary HCPs (PHCPs) play a crucial role in healthcare organization and patient communication. This study, conducted in February–March 2023, surveyed 1900 Belgian PHCPs to assess their views on periodic COVID-19 boosters for themselves and their patients. The survey included questions on sociodemographic information, willingness to receive periodic COVID-19 boosters, reasons for acceptance or refusal, confidence in vaccine safety and efficacy, and views on booster recommendations. Overall, 86% of participants were willing to receive periodic COVID-19 boosters, motivated by self-protection, patient well-being, and the uninterrupted delivery of healthcare services. Factors influencing booster refusal included not being a general practitioner (GP) or GP trainee, working in Wallonia or Brussels, and lacking vaccine confidence. Although 243 participants would not take boosters periodically, only 74 would not recommend it. Regarding administration, 59% supported pharmacist involvement in COVID-19 vaccination. Further qualitative analysis of 290 PHCPs' responses revealed varying recommendations, including specific roles like nurses, organizational structures, and collaborative approaches. This study highlights the need to address vaccine confidence, regional disparities, and PHCP roles in booster implementation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Predicting the next pandemic: VACCELERATE ranking of the World Health Organization's Blueprint for Action to Prevent Epidemics

Author

Salmanton-García, Jon, primary, Wipfler, Pauline, additional, Leckler, Janina, additional, Nauclér, Pontus, additional, Mallon, Patrick W., additional, Bruijning-Verhagen, Patricia C.J.L., additional, Schmitt, Heinz-Joseph, additional, Bethe, Ullrich, additional, Olesen, Ole F., additional, Stewart, Fiona A., additional, Albus, Kerstin, additional, Cornely, Oliver A., additional, Busch, Martin, additional, Seifert, Ulrike, additional, Widmer, Andreas, additional, Nagao, Miki, additional, Rello, Jordi, additional, Todorova, Tatina, additional, Cviljević, Sabina, additional, Heath, Christopher H., additional, Jančorienė, Ligita, additional, Fischer, Thea Koelsen, additional, Orth, Hans Martin, additional, Johansen, Isik Somuncu, additional, Doymaz, Mehmet, additional, Tragiannidis, Athanasios, additional, Löscher, Thomas, additional, Xu, Jin-Fu, additional, Husa, Petr, additional, Oteo, José Antonio, additional, Issack, Mohammad I., additional, Zeitlinger, Markus, additional, Le Grand, Roger, additional, Zdziarski, Przemysław, additional, Demirkan, Fatih, additional, Amador, Paloma Merino, additional, García-Lozano, Tomás, additional, Cao, Qing, additional, Vázquez, Lourdes, additional, Caeiro, Juan Pablo, additional, Hermans, Peter, additional, Nahrwar, Shahroch, additional, Avsar, Korkut, additional, Kumar, Deepak, additional, Fernández, Norma, additional, Mardani, Masoud, additional, Segal, Esther, additional, Pan, Angelo, additional, Gkentzi, Despoina, additional, Gioula, Georgia, additional, Cortés, Jorge Alberto, additional, Oliveira, Joaquim, additional, van Damme, Pierre, additional, Bin Mohd Zaili, Mohd Zaki, additional, Antinori, Spinello, additional, Zablockienė, Birutė, additional, Papazisis, Georgios, additional, Aneke, Chioma Inyang, additional, Valerio, Maricela, additional, McConkey, Samuel, additional, Aujayeb, Avinash, additional, Azzini, Anna Maria, additional, Roganović, Jelena, additional, Greve-Isdahl Mohn, Kristin, additional, Kremsner, Peter, additional, Gkrania-Klotsas, Effrossyni, additional, Corzo, Dora, additional, Khanna, Nina, additional, Smiatacz, Tomasz, additional, Scheithauer, Simone, additional, Merelli, Maria, additional, Klempa, Boris, additional, Vrḫovac, Radovan, additional, Ruggiero, Antonio, additional, Chaudhary, Pankaj, additional, Maquera-Afaray, Julio, additional, Ekkelenkamp, Miquel, additional, Jindra, Pavel, additional, Pantić, Nikola, additional, Guerra, Gemma Jiménez, additional, Weiss, Guenter, additional, Roohi, Behrad, additional, Argyropoulos, Christos D., additional, Silfverdal, Sven Aprne, additional, van Praet, Jens, additional, Bal, Zumrut Sahbudak, additional, Kanj, Souha, additional, Young, Barnaby, additional, Pana, Zoi Dorothea, additional, Roilides, Emmanuel, additional, Stearns, Stephen C., additional, Wauters, Joost, additional, Baño, Jesús Rodríguez, additional, Pletz, Mathias W., additional, Travar, Maja, additional, Kühn, Steven, additional, Riera, Fernando, additional, Cornely, Daniel, additional, Laura, Vlad Jeni, additional, Koehler, Philipp, additional, Eley, Brian, additional, Nair, Pravin K., additional, Ciesek, Sandra, additional, Olaru, Ioana Diana, additional, Marques, Laura, additional, Pontali, Emanuele, additional, Naunheim, Alexandra, additional, Lieb, Adrian, additional, Gerhard, Markus, additional, Farooqi, Joveria Qais, additional, Turtle, Lance, additional, Méndez, Gustavo Adolfo, additional, Cox, Rebecca Jane, additional, Goodman, Nigel, additional, Caceca, Billie, additional, Pemán, Javier, additional, Dawood, Halima, additional, Askling, Helena Hervius, additional, Fomsgaard, Anders, additional, Hernández, Alejandra Calderón, additional, Staehelin, Cornelia, additional, Liu, Chia-Ying, additional, Icardi, Giancarlo, additional, Castagnola, Elio, additional, Salzer, Helmut J.F., additional, Lundgren, Jens, additional, Javadli, Samir, additional, and Forghieri, Fabio, additional

Published
2024
Full Text
View/download PDF

33. The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium

Author

Poulimeneas, Dimitrios, primary, Koniordou, Markela, additional, Kousi, Dimitra, additional, Merakou, Christina, additional, Kopsidas, Ioannis, additional, Tsopela, Grammatiki Christina, additional, Argyropoulos, Christos D., additional, Themistocleous, Sophia C., additional, Shiamakkides, George, additional, Constantinou, Marinos, additional, Alexandrou, Alexandra, additional, Noula, Evgenia, additional, Nearchou, Andria, additional, Salmanton-García, Jon, additional, Stewart, Fiona A., additional, Heringer, Sarah, additional, Albus, Kerstin, additional, Álvarez-Barco, Elena, additional, Macken, Alan, additional, Di Marzo, Romina, additional, Luis, Catarina, additional, Valle-Simón, Paula, additional, Askling, Helena H., additional, Hellemans, Margot, additional, Spivak, Orly, additional, Davis, Ruth Joanna, additional, Azzini, Anna Maria, additional, Barta, Imre, additional, Součková, Lenka, additional, Jancoriene, Ligita, additional, Akova, Murat, additional, Mallon, Patrick W. G., additional, Olesen, Ole F., additional, Frias-Iniesta, Jesus, additional, van Damme, Pierre, additional, Tóth, Krisztina, additional, Cohen-Kandli, Miriam, additional, Cox, Rebecca Jane, additional, Husa, Petr, additional, Nauclér, Pontus, additional, Marques, Laura, additional, Ochando, Jordi, additional, Tacconelli, Evelina, additional, Zeitlinger, Markus, additional, Cornely, Oliver A., additional, Pana, Zoi Dorothea, additional, and Zaoutis, Theoklis E., additional

Published
2023
Full Text
View/download PDF

35. Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants

Author

Budroni, Sonia, Buricchi, Francesca, Cavallone, Andrea, Bourguignon, Patricia, Caubet, Magalie, Dewar, Vincent, D’Oro, Ugo, Finco, Oretta, Garçon, Nathalie, El Idrissi, Mohamed, Janssens, Michel, Leroux-Roels, Geert, Marchant, Arnaud, Schwarz, Tino, Van Damme, Pierre, Volpini, Gianfranco, van der Most, Robbert, Didierlaurent, Arnaud M., and Burny, Wivine

Published
2021
Full Text
View/download PDF

37. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses

Author

Wahid, Rahnuma, Mercer, Laina, Macadam, Andrew, Carlyle, Sarah, Stephens, Laura, Martin, Javier, Chumakov, Konstantin, Laassri, Majid, Petrovskaya, Svetlana, Smits, Saskia L., Stittelaar, Koert J., Gast, Chris, Weldon, William C., Konopka-Anstadt, Jennifer L., Steven Oberste, M., Van Damme, Pierre, De Coster, Ilse, Rüttimann, Ricardo, Bandyopadhyay, Ananda, and Konz, John

Published
2021
Full Text
View/download PDF

48. Estimating infectious disease parameters from data on social contacts and serological status

Author

Goeyvaerts, Nele, Hens, Niel, Ogunjimi, Benson, Aerts, Marc, Shkedy, Ziv, Van Damme, Pierre, and Beutels, Philippe

Subjects
Statistics - Applications
Abstract

In dynamic models of infectious disease transmission, typically various mixing patterns are imposed on the so-called Who-Acquires-Infection-From-Whom matrix (WAIFW). These imposed mixing patterns are based on prior knowledge of age-related social mixing behavior rather than observations. Alternatively, one can assume that transmission rates for infections transmitted predominantly through non-sexual social contacts, are proportional to rates of conversational contact which can be estimated from a contact survey. In general, however, contacts reported in social contact surveys are proxies of those events by which transmission may occur and there may exist age-specific characteristics related to susceptibility and infectiousness which are not captured by the contact rates. Therefore, in this paper, transmission is modeled as the product of two age-specific variables: the age-specific contact rate and an age-specific proportionality factor, which entails an improvement of fit for the seroprevalence of the varicella-zoster virus (VZV) in Belgium. Furthermore, we address the impact on the estimation of the basic reproduction number, using non-parametric bootstrapping to account for different sources of variability and using multi-model inference to deal with model selection uncertainty. The proposed method makes it possible to obtain important information on transmission dynamics that cannot be inferred from approaches traditionally applied hitherto., Comment: 25 pages, 6 figures

Published
2009

50. Diagnosing Viral Infections Through T-Cell Receptor Sequencing of Activated CD8+ T Cells

Author

Vujkovic, Alexandra, primary, Ha, My, additional, de Block, Tessa, additional, van Petersen, Lida, additional, Brosius, Isabel, additional, Theunissen, Caroline, additional, van Ierssel, Sabrina H, additional, Bartholomeus, Esther, additional, Adriaensen, Wim, additional, Vanham, Guido, additional, Elias, George, additional, Van Damme, Pierre, additional, Van Tendeloo, Viggo, additional, Beutels, Philippe, additional, van Frankenhuijsen, Maartje, additional, Vlieghe, Erika, additional, Ogunjimi, Benson, additional, Laukens, Kris, additional, Meysman, Pieter, additional, and Vercauteren, Koen, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results